We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.14 | -0.35% | 39.87 | 1,274 | 09:47:52 |
From Jul 2022 to Jul 2024
By Michael Susin
GSK PLC said Thursday that a Phase 3 trial of its respiratory syncytial virus vaccine candidate for adults aged over 60 years met its primary endpoint.
The U.K.-based maker of cancer and asthma medications said that the vaccine candidate study showed a 94.1% reduction in severe RSV disease, and overall vaccine efficacy of 82.6%, meeting the trial's primary endpoint. The vaccine was also well tolerated with a favorable safety profile, it added.
GSK said that regulatory submissions based on the results are anticipated in the second half of 2022.
"These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research," Chief Scientific Officer Tony Wood said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
October 13, 2022 02:30 ET (06:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
